Trial Profile
A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Patidegib (Primary)
- Indications Chondrosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Infinity Pharmaceuticals
- 11 Jan 2022 This trial has been completed in Norway (End Date: 15 Oct 2013), according to European Clinical Trials Database record.
- 18 Jun 2012 Status changed from recruiting to discontinued, according to an Infinity Pharmaceuticals media release.
- 02 Jun 2012 Additional lead trial investigator identified as reported by Oregon Health and Science University Institutional Review Board.